Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 170

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 8
Chunk 170
---
 unrealized loss position at June 30, 2025 and December 31, 2024 was $626.8 million and $768.1 million, respectively. There were no individual securities that were in a significant unrealized loss position as of June 30, 2025 and December 31, 2024. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of June 30, 2025 and December 31, 2024.

5. Inventory

Inventory, which consists of commercial supply of PYRUKYND®, consisted of the following:(In thousands)June 30,2025December 31, 2024Raw materials$89 $89 Work-in-process27,207 24,509 Finished goods3,552 3,018 Total inventory$30,848 $27,616 

6. Leases

Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of approximately three years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. The components of lease expense and other information related to leases were as follows:Three Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Operating lease costs$3,806 $3,806 $7,613 $7,613 Cash paid for amounts included in the measurement of operating lease liabilities4,911 4,678 9,748 9,331 We have not entered into any material short-term leases or financing leases as of June 30, 2025.In arriving at the operating lease liabilities as of June 30, 2025 and December 31, 2024, we applied the weighted-average incremental borrowing rate of 5.7% for both periods over a weighted-average remaining lease term of 2.7 and 3.2 years, respectively. As of June 30, 2025, undiscounted minimum rental commitments under non-cancelable leases were as follows:(In thousands)Remaining 2025$8,195 202620